// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























3441 Abstracts

Study on the relationship between microsatellite status and clinicopathological characteristics of colorectal cancer patients after surgery.

Meili Chen - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Prognostic impact of PIK3CA mutation in esophageal cancer: Molecular profiling by next-generation sequencing using formalin-fixed, paraffin-embedded tissues.

Tomoya Yokota - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Role of ERBB receptor feedback inhibitor 1 (ERRFI1) downregulation in progression of premalignant oral lesions to cancer.

Prajwal A - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Use of molecular testing and EGFR targeted medications for colorectal cancer at VA Hospitals.

Daniel Jacob Becker - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Erbitux

An internet-based survey of factors influencing patients satisfaction score and factors leading to discontinuation of treatment in lung cancer patients in China.

Weini Qiu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Improvement of EGFR testing under multidisciplinary care: A retrospective chart analysis.

Margaret Griffin Crawford - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Co-mutations in surgically resected and EGFR mutated lung adenocarcinoma: A subset analysis of the large prospective cohort study.

Kenji Sawa - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Trends in non-small cell lung cancer biomarker testing rates in the US and Western Europe from 2014-2017.

Bijal Shah-Manek - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

EGFR to regulate angiogenesis in intact and tumor skin tissues in 16/F10 melanoma with chronic pain.

I. M. Kotieva - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Chronic pain and accumulation of growth factors in perifocal tissues of melanoma and impact on malignancy and early metastasis.

I. M. Kotieva - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

FGF-21

Implementation of the genereader NGS system in a molecular pathology laboratory.

Andreas Bosl - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Oncogenic mutation within the 3-C loop of EGFR/ERBB2/BRAF/MAP2K1.

Jie Gao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Do high VEGFA and EGF levels in blood indicate liver metastases only?

Irina V. Kaplieva - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer.

Lance G. Laing - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pertuzumab

An enhanced next-generation sequencing liquid biopsy assay for simultaneous detection of somatic variants, microsatellite instability and viral DNA.

Yukti Choudhury - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A CODAR-PCR assay using nucleic acids extracted from whole blood samples to provide superior sensitivity in EGFR T790M mutation detection and accurate prediction of osimertinib response in advanced NSCLC patients.

Qiong Zhao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tagrisso

Phase 0/1 of positron emission tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC).

Alexandre Cochet - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Biology and clinical outcomes of estrogen receptor positive (ER+) early primary breast cancer (BC) in older (70 years) womenA study based on core needle biopsies (CNB).

Kwok-Leung Cheung - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

EFIRM liquid biopsy (eLB): Detection of ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients.

Feng Li - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Technical validation of the electric field-induced release and measurement (EFIRM) assay for the detection of EGFR mutations in circulating cell free DNA in plasma and saliva.

Fang Wei - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved